Distribution via pharmacies in the UK and Australia is underway.
Intercure Ltd. (TASE:INCR) has begun building a second distribution channel for its Respirate device for the treatment of hypertension through pharmacies. The company has signed a wholesaler agreement with UK distributor Mashco Ltd. and with an Australian distributor.
Until now, Intercure mainly sold the Respirate device to private consumers via the Internet and by direct phone sales. The company posted NIS 18 million in sales in the first half of 2007, mostly in the US. The US Food and Drug Administration (FDA) approved the device for the lowing of high blood pressure.
Mashco, a leading distributor to independent pharmacies, will initially sell the Respirate to 100 pharmacies, with a focus on pharmacies that also provide hypertension measurement services, and will later expand sales to 3,000 pharmacies across the UK. The Australian distributor will initially sell the Respirate at 300 points of sale owned by three pharmacy chains.
Published by Globes [online], Israel business news - www.globes.co.il - on September 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007